ORIC PHARMACEUTICALS, INC. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- ORIC PHARMACEUTICALS, INC. stock issued during period, value, new issues for the quarter ending 2026-03-31 was $59.89M.
- ORIC PHARMACEUTICALS, INC. stock issued during period, value, new issues for the quarter ending 2025-09-30 was $108.70M.
- ORIC PHARMACEUTICALS, INC. stock issued during period, value, new issues for the quarter ending 2025-06-30 was $133.27M.
- ORIC PHARMACEUTICALS, INC. stock issued during period, value, new issues for the quarter ending 2024-03-31 was $124.83M.
- ORIC PHARMACEUTICALS, INC. stock issued during period, value, new issues for fiscal 2025 was $241.97M, a 93.84% increase from fiscal 2024.
- ORIC PHARMACEUTICALS, INC. stock issued during period, value, new issues for fiscal 2024 was $124.83M, a 47.25% increase from fiscal 2023.
- ORIC PHARMACEUTICALS, INC. stock issued during period, value, new issues for fiscal 2023 was $84.77M, a 239.10% increase from fiscal 2022.
- ORIC PHARMACEUTICALS, INC. stock issued during period, value, new issues for fiscal 2022 was $25.00M, a 50.00% decline from fiscal 2021.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2026-03-31 | $59.89M 10-Q · filed 2026-08-03 | |
| 2025-12-31 | $241.97M 10-K · filed 2026-02-23 | |
| 2025-09-30 | $108.70M 10-Q · filed 2025-11-13 | |
| 2025-06-30 | $133.27M 10-Q · filed 2026-08-03 | |
| 2024-12-31 | $124.83M 10-K · filed 2026-02-23 | |
| 2024-03-31 | $124.83M 10-Q · filed 2025-11-13 | |
| 2023-12-31 | $84.77M 10-K · filed 2025-02-18 | |
| 2023-06-30 | $84.77M 10-Q · filed 2024-11-12 | |
| 2022-12-31 | $25.00M 10-K · filed 2024-03-11 | |
| 2021-12-31 | $50.00M 10-K · filed 2023-03-16 | |
| 2021-09-30 | $50.00M 10-Q · filed 2022-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |